Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2025)

C4 Therapeutics' Current Deferred Revenue history spans 7 years, with the latest figure at $28.3 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 51.42% year-over-year to $28.3 million; the TTM value through Dec 2025 reached $28.3 million, up 51.42%, while the annual FY2025 figure was $28.3 million, 51.42% up from the prior year.
  • Current Deferred Revenue reached $28.3 million in Q4 2025 per CCCC's latest filing, up from $17.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $43.8 million in Q2 2025 to a low of $8.4 million in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $25.0 million, with a median of $24.4 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: plummeted 75.86% in 2023, then soared 161.91% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $31.8 million in 2021, then tumbled by 47.74% to $16.6 million in 2022, then dropped by 6.9% to $15.5 million in 2023, then increased by 20.95% to $18.7 million in 2024, then skyrocketed by 51.42% to $28.3 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Current Deferred Revenue are $28.3 million (Q4 2025), $17.1 million (Q3 2025), and $43.8 million (Q2 2025).